Примери за използване на Initial doses на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Initial doses.
The recommended initial doses are.
After the initial doses, it is usually given once every 8 weeks.
A booster dose should be given at least six months after the last of these initial doses.
Low initial doses of 0.15- 0.3 mg given as a daily subcutaneous injection.
Patients should be particularly carefully monitored if given higher initial doses(12 mg per kg body-weight twice daily).
The recommended initial doses presented below are intended to act solely as a guideline.
Since barbiturates aremetabolized in the liver, they should be used with caution and initial doses should be small in.
Use of lower initial doses has been reported, but has not been studied systematically.
The first injection should be given no earlier than 3 months of age if two initial doses are given; the interval between injections should be at least 2 months.
High initial doses of lamotrigine and exceeding the recommended dose escalation of.
In situations of less severity lower doses will generally suffice, while in selected patients prednisone higher initial doses may be required.
The recommended initial doses presented below are intended to act solely as a guideline.
In situations of less severity lower doses will be sufficient whereas in certain patients higher initial doses of Methylprednisolone Tablets may be required.
Low initial doses of 0.15- 0.3 mg injected each day under the skin(subcutaneous injection).
General considerations The recommended initial doses presented below are intended to act solely as a guideline.
Initial doses of 5 mg/kg/day are justified in patients whose condition requires rapid improvement.
At the start of somatropin therapy, low initial doses of 0.15- 0.3 mg are recommended, given as a daily subcutaneous injection.
Initial doses immediately after transplantation are generally on the order of 0.075 mg- 0.30 mg/ kg weight/ day in dependence of the transplanted organ.
Since barbiturates are metabolized in the liver,they should be used with caution and initial doses should be small in patients with hepatic dysfunction.
This includes initial doses as well as doses for maintenance treatment and doses to be used in patients with reduced kidney function.
Reproductive toxicology studies have been conducted in pregnant cynomolgus monkeys(Gestational Day(GD)19 through to GD 50) at initial doses of 30 to 150 mg/kg followed by bi-weekly doses of 10 to 100 mg/kg.
Initial doses just after transplantation will generally be in the range of 0.075- 0.30 mg per kg body weight per day depending on the transplanted organ.
Prescribers should assess the need for escalation to maintenance dose when restarting Lamictal in patients who have discontinued Lamictal for any reason,since the risk of serious rash is associated with high initial doses and exceeding the recommended dose escalation for lamotrigine(see section 4.4).
High initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy(see section 4.2)- concomitant use of valproate(see section 4.2).
As a consequence of the higher initial doses and longer maintenance therapy required after transplantation, side effects are more frequent and usually more severe in transplant patients than in patients treated for other indications.
Initial doses should be lower and subsequent dose titration should be more gradual because of greater chance of undesirable effects especially in very old and frail patients.
In controlled trials of adalimumab(initial doses of 160 mg at week 0 and 80 mg at week 2, followed by 40 mg every week starting at week 4), in patients with hidradenitis suppurativa with a control period duration ranging from 12 to 16 weeks, ALT elevations≥ 3 x ULN occurred in 0.3% of adalimumabtreated patients and 0.6% of control-treated patients.
Initial doses of 60 U/kg of body weight once every 2 weeks have shown improvement in haematological and visceral parameters within 6 months of therapy and continued use has either stopped progression of or improved bone disease.
Elderly Initial doses should be lower and subsequent dose titration should be more gradual because of greater chance of undesirable effects especially in very old and frail patients.